These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 38092484)

  • 1. When to use which molecular prognostic scoring system in the management of patients with MDS?
    Kewan T; Bewersdorf JP; Gurnari C; Xie Z; Stahl M; Zeidan AM
    Best Pract Res Clin Haematol; 2023 Dec; 36(4):101517. PubMed ID: 38092484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does mutational burden add to other prognostic factors in MDS?
    Nazha A
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101098. PubMed ID: 31779975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic scoring systems and risk stratification in myelodysplastic syndrome: focus on integration of molecular profile.
    Ball S; Komrokji RS; Sallman DA
    Leuk Lymphoma; 2022 Jun; 63(6):1281-1291. PubMed ID: 34933652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk stratifying MDS in the time of precision medicine.
    Cazzola M
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):375-381. PubMed ID: 36485160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
    Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
    BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic strategies in low and high-risk MDS: What does the future have to offer?
    Scalzulli E; Pepe S; Colafigli G; Breccia M
    Blood Rev; 2021 Jan; 45():100689. PubMed ID: 32253020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytogenetics and molecular genetics of myelodysplastic neoplasms.
    Ning Y; Zhang Y; Kallen MA; Emadi A; Baer MR
    Best Pract Res Clin Haematol; 2023 Dec; 36(4):101512. PubMed ID: 38092472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular international prognostic scoring system for myelodysplastic syndromes].
    Nagata Y
    Rinsho Ketsueki; 2023; 64(5):355-368. PubMed ID: 37271526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2023 Aug; 98(8):1307-1325. PubMed ID: 37288607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The MDS genomics-prognosis symbiosis.
    Nazha A
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):270-276. PubMed ID: 30504321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome.
    Xian RR
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):51-58. PubMed ID: 38066895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Acute Myeloid Leukemia Progression on the Prognosis of 831 Patients With Myelodysplastic Syndromes From the Argentine Database.
    Enrico A; Bestach Y; Flores MG; Arbelbide J; Serale C; Novoa V; Crisp R; Rivas MM; Larripa I; Belli C
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):743-752.e5. PubMed ID: 28797621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current state of treatment for myelodysplastic syndromes].
    Ichikawa M
    Rinsho Ketsueki; 2023; 64(9):988-997. PubMed ID: 37793875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
    Bernard E; Tuechler H; Greenberg PL; Hasserjian RP; Arango Ossa JE; Nannya Y; Devlin SM; Creignou M; Pinel P; Monnier L; Gundem G; Medina-Martinez JS; Domenico D; Jädersten M; Germing U; Sanz G; van de Loosdrecht AA; Kosmider O; Follo MY; Thol F; Zamora L; Pinheiro RF; Pellagatti A; Elias HK; Haase D; Ganster C; Ades L; Tobiasson M; Palomo L; Della Porta MG; Takaori-Kondo A; Ishikawa T; Chiba S; Kasahara S; Miyazaki Y; Viale A; Huberman K; Fenaux P; Belickova M; Savona MR; Klimek VM; Santos FPS; Boultwood J; Kotsianidis I; Santini V; Solé F; Platzbecker U; Heuser M; Valent P; Ohyashiki K; Finelli C; Voso MT; Shih LY; Fontenay M; Jansen JH; Cervera J; Gattermann N; Ebert BL; Bejar R; Malcovati L; Cazzola M; Ogawa S; Hellström-Lindberg E; Papaemmanuil E
    NEJM Evid; 2022 Jul; 1(7):EVIDoa2200008. PubMed ID: 38319256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes.
    Minetto P; Guolo F; Clavio M; De Astis E; Colombo N; Grasso R; Fugazza G; Sessarego M; Lemoli RM; Gobbi M; Miglino M
    Leuk Res; 2015 Aug; 39(8):866-73. PubMed ID: 26012361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations.
    West AH; Godley LA; Churpek JE
    Ann N Y Acad Sci; 2014 Mar; 1310(1):111-8. PubMed ID: 24467820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility and real-world application of molecular genetic sequencing in the management of patients with acute myeloid leukemia and myelodysplastic syndromes.
    Banaszak LG; Reinig E; Lasarev MR; Mattison RJ
    Leuk Lymphoma; 2022 Mar; 63(3):684-693. PubMed ID: 34865601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age.
    Xie Z; Chen EC; Stahl M; Zeidan AM
    Blood Rev; 2023 May; 59():101033. PubMed ID: 36357283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study.
    GenoMed4All consortium
    Lancet Haematol; 2023 Feb; 10(2):e117-e128. PubMed ID: 36436542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.